Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label intrathecal MELPIDA trial in SPG50 with matched concurrent control
2025-524576-28-00Phase 3Authorised
- Sponsor
- Elpida Therapeutics
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 2
01
Overview
Phase 3, open-label trial of MELPIDA in Hereditary spastic paraplegia type 50 (SPG50) (2 arms), sponsored by Elpida Therapeutics. Primary endpoint: 8 Major Milestones Total Score trajectory. Planned start Jul 2026; status: authorised.
02
Drugs
MELPIDA
03
Conditions
Hereditary spastic paraplegia type 50 (SPG50)
Beyond the preview
Go deeper on 2025-524576-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524576-28-00.